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Abstract
Estradiol (E) is a multitasking hormone that plays a prominent role in the reproductive
system, and also contributes to physiological and growth mechanisms throughout
the body. Frisina and colleagues have previously demonstrated the beneficial effects
of this hormone, with E‐treated subjects maintaining low auditory brainstem re‐
sponse (ABR) thresholds relative to control subjects (Proceedings of the National
Academy of Sciences of the United States of America, 2006;103:14246; Hearing Research,
2009;252:29). In the present study, we evaluated the functionality of the peripheral
and central auditory systems in female CBA/CaJ middle‐aged mice during and after
long‐term hormone replacement therapy (HRT) via electrophysiological and molecu‐
lar techniques. Surprisingly, there are very few investigations about the side effects
of HRT in the auditory system after it has been discontinued. Our results show that
the long‐term effects of HRT are permanent on ABR thresholds and ABR gap‐in‐
noise (GIN) amplitude levels. E‐treated animals had lower thresholds and higher am‐
plitude values compared to other hormone treatment subject groups. Interestingly,
progesterone (P)‐treated animals had ABR thresholds that increased but amplitude
levels that remained relatively the same throughout treatment. These results were
consistent with qPCR experiments that displayed high levels of IGF‐1R in the stria
vascularis (SV) of both E and P animal groups compared to combination treatment
(E + P) animals. IGF‐1R plays a vital role in mediating anti‐apoptotic responses via the
PI3K/AKT pathway. Overall, our findings gain insights into the neuro‐protective
properties of E hormone treatments as well as expand the scientific knowledge base
to help women decide whether HRT is the right choice for them.
KEYWORDS

age‐related hearing loss, aging, auditory system, hormone replacement therapy, HRT,
neurodegeneration
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Consequently, researchers and clinicians have been assessing the
benefits and risks of HRT. Studies such as the Woman's Health

Hormone replacement therapy (HRT) is the most commonly sought

Initiative (WHI) and Heart Estrogen‐Progestin Replacement Study

out therapeutic intervention to relieve menopausal symptoms.

(HERs) have evaluated the effects HRT has on blood pressure, breast
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provided the original work is properly cited.
© 2019 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Aging Cell. 2019;18:e12939.
https://doi.org/10.1111/acel.12939



wileyonlinelibrary.com/journal/acel

|

1 of 15

2 of 15

|

WILLIAMSON et al.

cancer, cervical cancer, osteoporosis, stroke, and heart disease for

because of their involvement in anti‐apoptotic responses and cell

menopausal women (Hulley et al., 1998; Ness, Aronow, Newkirk,

survival. The stria vascularis (SV) is a specialized cochlear tissue re‐

& McDanel, 2005). The controversial findings from these studies

sponsible for maintaining endolymph ionic concentrations as well as

swayed the decision of many women that were considering or cur‐

generating the endocochlear potential (EP). With age, EP cell health

rently undergoing HRT to avoid or discontinue treatment. Despite

and ion levels start to decline due to cellular degeneration in the

this, there are still millions of middle‐aged women in the United

SV, which compromises auditory function. Considering this, qPCR

States and worldwide who are presently undergoing hormone ther‐

experiments were performed with SV lateral wall cells extracted

apy in an effort to relieve severe menopausal symptoms, aid in lim‐

from the cochlea of each animal in the hormone groups post‐treat‐

iting osteoporosis, and reduce the risk of colon cancer (Ness et al.,

ment (in vivo) and in SVK‐1 cells (epithelial cells derived from the SV

2005). Most recently, research has indicated an additional benefit of

of the P14 Immortomouse) treated with HRT over various lengths

certain types of hormone therapy—hearing protection. There have

of time (in vitro) to evaluate the expression levels of IGF‐1R and

been various reports of estradiol (E) hormone therapy improving

FoxO3. The findings from this study will indicate whether there is

distortion product otoacoustic emissions (DPOAEs) as well as audi‐

cross talk between E, IGF‐1R, and FoxO3 via the PI3K/AKT path‐

tory brainstem response (ABR) amplitudes and latencies (Coleman,

way, which contributes to the delayed onset of ARHL observed

Campbell, Cooper, Welsh, & Moyer, 1994; Curhan et al., 2017; Milon

during HRT with E in vivo.

et al., 2018; Price, Zhu, Guimaraes, Vasilyeva, & Frisina, 2009; Zhang

Novel aspects of the present study include (a) treating animals

et al., 2018). For example, Barati et al. (2013) reported that after

with hormone therapy over an extended period of 6 months, (b) ad‐

30 days of E hormone treatment patients with conductive hearing

ministering P alone to evaluate its sole effect on auditory system

loss displayed improvements in ABR thresholds compared to con‐

processing, (c) evaluating the aftermath of HRT on the aging cochlea,

trol subjects. Contrarily, combination treatment (E + progesterone

and (d) examining the relationships between the IGF‐1 pathway and

[P]) has been shown to have a negative effect on auditory function.

the protective properties of E. The discoveries from this experimen‐

Some studies have suggested that P is the negative component in

tation will help to gain better insights as to how E preserves cellu‐

the E + P combination, since combination treatment has detrimental

lar functionality in the aging auditory system via neuro‐protective

effects on auditory processing. In 2006, Guimaraes et al. reported

properties, which could lead to future enhancements in therapeutic

that P was the negative component for the E + P treatment duo since

solutions for preventing or treating key aspects of age‐related hear‐

women who were treated with E + P had significantly higher ABR

ing loss (ARHL).

thresholds than E‐treated and age‐matched control patients. Their
study concluded that the beneficial neural excitability activated by E
may be counterbalanced by P's activation of inhibitory gamma‐ami‐

2 | R E S U LT S

nobutyric acid (GABA) neurons. The specific actions of P on the au‐
ditory system, that is, benefits and/or risks of administering P alone,
are still unknown.

For the present study, CBA/CaJ middle‐aged mice underwent base‐
line auditory brainstem response (ABR) and ABR gap‐in‐noise (GIN)

Although most studies have focused on the influence of HRT

electrophysiological testing at 15 months of age. All of the female

during treatment, no studies have specifically evaluated hearing

animals underwent an ovariectomy procedure, where both sets of

changes after hormone therapy has ended. Researchers have yet

ovaries were removed, at the outset of the study, once baseline

to fully understand the health benefits and risks of discontinuing

hearing testing was complete. This was done to ensure that natu‐

hormone therapy, that is, are its effects reversible? In light of this,

rally occurring sex hormones would not add variability to the female

our study was designed to evaluate the hearing of ovariectomized

hormone levels during mouse “menopause/estropause.” The females

(OVX) female CBA/CaJ middle‐aged mice undergoing HRT for

were then randomly placed in hormone treatment groups: E‐estra‐

a period of 6 months, and then after discontinuing treatment for

diol 17β (n = 16, 0.006 mg/day), P (n = 12, 0.40 mg/day), E + P (n = 12,

1 month. Subjects were randomly placed into hormone groups: E, P,

0.40 mg/day +0.006 mg/day), and placebo (Pb, n = 13). The hormone

E + P, and placebo (Pb). The full effects of P on hearing are still quite

treatments utilized for the following investigation were optimal HRT

understudied as previously mentioned, which is why a unique P‐

concentrations obtained from previous studies by Guimaraes et al.

only group was incorporated here. ABR and ABR gap‐in‐noise (GIN)

(2006) and Price et al. (2009). It should be noted that a group of

are electrophysiological techniques used to record and analyze the

males, also 15 months old at study onset, served as a comparison

responses of auditory nerve and brainstem activity and temporal

control group. The animals went through hormone treatment for a

processing, respectively. To further expand on the results obtained

duration of 6 months. Subsequently, a 1‐month washout/recovery

for these electrophysiology hearing tests, molecular biology ex‐

period was followed to see whether the effects of the hormones

periments were performed to evaluate the expression of insulin

were ongoing or reversible.

growth factor 1 receptor (IGF‐1R) and forkhead box O3 (FoxO3) in

Auditory brainstem response (ABR) tests evaluate not only the

the cochlea during hormone therapy, from both in vitro and in vivo

cochlear output (Peak 1: P1) but also the brainstem pathways that

perspectives. Both of these gene pathways play significant roles in

subserve hearing as well. A short duration sound is presented to

influencing the PI3K/AKT pathway and were specifically chosen

the ear of the animal and an EEG waveform response is generated.

|
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F I G U R E 1 Auditory brainstem response (ABR) and ABR gap‐in‐noise techniques. (a) Five to seven waves are typically generated during
Auditory Brainstem Response (ABR) testing for humans clinically, and animals such as mice. Starting at 90 decibels (dB), various frequencies
(3–48 kHz) are presented at sound levels that decrease in intervals of 5 dB. The threshold is considered the lowest sound level at which
a waveform can be detected. The figure shows the ABR results for a 15‐month‐old CBA/CaJ mouse at 90 decibels (dB). (b) The ABR gap‐
in‐noise (GIN) technique measures auditory temporal processing. Subjects were presented with a 25‐millisecond (ms) noise burst (NB1)
followed by a series of silent gap durations, ranging from 0 to 64 ms. A second 25‐ms noise bursts (NB2) was presented to measure the
ability of the auditory system to recover from NB1 and efficiently respond to NB2. For the present study, the ABR GIN analysis focused on
the amplitude levels (red arrow) for Peak 1 and Peak 4. The figure displays the baseline ABR GIN response at 8 ms for a 15‐month‐old mouse

Each peak of this waveform response is produced from a partic‐
ular level or nucleus of the auditory brainstem. Specifically for
ABRs, P1 is used to determine the threshold for tone pip fre‐
quencies ranging from 3 to 48 kHz as well as a wideband noise

2.1 | Hormonal influences on absolute
sensitivity of hearing
Averaged ABR thresholds in Figure 2 depict the changes that each of the

(WBN) stimulus (Figure 1a). The lowest sound level, in decibels

hormone groups underwent during HRT over time (FTime [9, 208] = 21.31,

(dB), where P1 can be identified is recognized as the threshold.

p < 0.0001). Very few changes were seen in the E animal thresholds over

A novel paradigm known as ABR gap‐in‐noise (GIN) was used to

the treatment period compared to the other groups (Figure 2). Statistical

test auditory temporal processing. The ABR GIN technique uses

differences were only seen at 6 and 20 kHz between the baseline and 3‐

the same basic sounds that elicit ABRs to measure the tempo‐

month checkpoints (Refer to Supporting Information Table S1, Datasheet).

ral processing abilities of subjects at various sound gap intervals

Meanwhile, E + P‐treated animals displayed significant increases in ABR

(Figure 1b). P1 and P4 amplitude levels measure the intensity as

thresholds during HRT as illustrated in Figure 2c. Indeed, differences were

well the synchronization of neurons from the auditory nerve and

seen once treatment ended, especially at 6 kHz, 36 kHz, and for WBN.

inferior colliculus, respectively, when a noise stimulus has been

Interestingly, P and Pb animals had the worst hearing thresholds among

presented (Williamson, Zhu, Walton, & Frisina, 2015). These hear‐

all of the hormone groups during the 6 months of treatment as well as

ing tests allowed us to gain better insights into the various stages

during the 1‐month recovery period. The P group's thresholds began to

of the aging process in the auditory system, using declining am‐

significantly increase as early as 3 months after treatment began, espe‐

plitude levels and high thresholds as an indicator of presbycusis.

cially for high frequencies (Figure 2b). Supporting Information Table S1

Further details and explanations about ABRs and ABR GIN test‐

shows a notable increase in the ABR thresholds at 36 and 48 kHz at the

ing techniques can be found in our previous, detailed report by

3‐month checkpoint. By 6 months, almost all of the thresholds rose sig‐

Williamson et al. (2015).

nificantly for all of the tested frequencies, relative to the pretreatment

|
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F I G U R E 2 Auditory brainstem response thresholds over the course of hormone treatments as well as during the recovery period. (a)
E animals show no significant signs of ARHL over the course of hormone therapy, thus indicating that E possesses protective properties
for auditory function. (b) P animals show significantly poorer hearing at almost all of the tested frequencies. (c) The E + P group displayed
elevations in ABR thresholds as early as 3 months. Notable worsening of hearing could be seen in this group over time. (d) Pb control
animals’ thresholds changed drastically over the 6‐month time period. Significant ARHL changes were observed for all frequencies. (e)
Changes observed in the male group, more specifically during the recovery period (8 months), could be attributed to ARHL. (f) Recovery
period group comparison shows that E‐treated animals had lower thresholds at 12, 16, 20, 24, and 32 kHz compared to all the other HRT
animals. Pb females had higher thresholds among the HRT groups at 24 and 32 kHz. These data, in conjunction with Figure 5, suggest that
the results of long‐term HRT on ABR thresholds are permanent. No statistical differences were seen among the hormone groups during
the recovery period. It should be noted that statistical differences for (a) through (e) are a comparison between the baseline and recovery.
Statistical test: 2‐way ANOVA followed by Bonferroni; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
baseline. Post‐treatment ABR thresholds were higher than thresholds

receiving HRT had a substantial impact on Pb animals. ABR thresholds for

during treatment and significantly so compared to baseline thresholds.

the male group displayed age‐linked threshold elevations throughout the

Similarly, Pb animals’ auditory function worsened over time during the

experiment (Figure 2e). The considerable differences seen in the recov‐

experiment. Escalated thresholds were observed 3‐month postovariec‐

ery/washout period, similar to the E + P group, can be attributed to the

tomy surgery and continued to rise for the remainder of the experiment

progression of ARHL for this male control group. Figure 2f shows a com‐

(Figure 2d). Threshold shifts for this particular group were as high as

parison all of the hormone groups post‐treatment (FHRT [4,241] = 6.215,

10 dB for the higher frequencies, thus indicating that the loss of E without

p < 0.0001). No significant differences were found among the groups at

|
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F I G U R E 3 Auditory brainstem response gap‐in‐noise P1 amplitude levels for NB2 for subject groups during HRT and for the recovery
period. (a) Few changes were observed in E‐treated animals during the course of the longitudinal experiment. Significant changes were only
seen at the largest gap interval, 64 ms. (b) The P group displayed greater declines while undergoing long‐term HRT. (c) Amplitude levels were
sharply reduced once treatment began for E + P animals. Significant changes were seen as early as 3 months at 8, 32, and 64 ms. (d) ARHL
was observed in Pb animals throughout the course of the experiment. These changes could have been exacerbated due to the removal of E
from the circulatory system during middle age. (e) The males also displayed signs of presbycusis throughout the course of the experiment,
as steep declines were detected for P1 amplitude levels. These findings suggest that females treated with E or P retain temporal processing
abilities better than males. No signs of recovery were observed in any of the subject groups. Statistical test: 2‐way ANOVA followed by
Bonferroni; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
the checkpoint; however, the thresholds for the E animals were slightly

over time compared to the other subject groups. For instance, P1 am‐

lower than all of the other groups, specifically at 12, 16, 20, and 24 kHz.

plitudes ranged from 1.01 mV to 0.85 mV at 16 ms for the baseline
and 6‐month checkpoint, respectively. Notable changes were only

2.2 | Hormonal influences on changes in auditory
temporal processing

seen at 64 ms for 3 and 6 months, as seen in Figure 3a. Interestingly,
the P group's amplitude levels exhibited a gradual decline as treatment
progressed. For instance, amplitude levels dwindled from 1.71 mV to

Longitudinal ABR GIN amplitude values for P1 were compared for

1.49 mV at 64 ms for the baseline compared to the 3‐month check‐

each of the HRT groups, as seen in Figure 3. Similar to ABR thresh‐

point. After 6 months of treatment, this value continued to decrease

olds, E‐treated animals had P1 amplitude levels that minimally declined

by 0.43 mV, relative to the 3‐month value. For this particular group,
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F I G U R E 4 Auditory brainstem response gap‐in‐noise P4 amplitude levels for NB2 for subject groups during HRT and for the recovery
period. (a) Amplitude levels for E‐treated animals decline marginally once treatment began. (b) The P group amplitude levels showed a steady
decline throughout the advancement of treatment, with the largest differences seen during the recovery period. (c) E + P animals also
displayed a significant decrease in P4 amplitude levels. Most striking differences were observed during the recovery period. (d) Amplitude
values declined as early as 3 months for Pb animals. This group exhibited the worst reduction in amplitude levels among the female
groups. (e) The males also showed signs of ARHL at longer gap intervals, starting at 16 ms. All of the groups, except E displayed changes
during recovery, that is, for these groups P4 amplitudes worsened after HRT was discontinued. Statistical test: 2‐way ANOVA followed by
Bonferroni; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

meaningful differences were seen in Figure 3b at wider gap durations:

displayed for this group. Contrary to what was seen with ABR thresh‐

32 and 64 ms. Recovery amplitude values for these animals were rela‐

olds, E + P had more of a negative effect on ABR GIN amplitude levels

tively similar to 6‐month values, which suggests that there is no recov‐

than P. Additionally, differences for P1 amplitude levels in female mice

ery from P treatment. As presented in Figure 3c, E + P P1 amplitude

were seen in the Pb group. Gradual decreasing values were observed

levels declined radically by 3 months of treatment. Baseline values that

at the smaller gap durations (Figure 3d). Nonetheless, considerable

started at 1.87 mV were abruptly reduced to 1.11 mV, 3 months after

declines were seen as early as 3 months by 32 ms. The male group ex‐

HRT began, for the 64‐ms gap interval. This decline remained reason‐

hibited a sharp reduction in P1 amplitude levels for each of the gap in‐

ably consistent throughout the course of treatment. Significant differ‐

tervals as well. Parallel to Pb animals, statistical differences were seen

ences were seen in gap durations of 8, 32, and 64 ms. No recovery was

at 6 months into the experiment for smaller gap durations; meanwhile,
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F I G U R E 5 In vitro quantitative IGF‐1R and FoxO3 gene expression in SVK‐1 cells after different time intervals for the duration of HRT.
(a) IGF‐1R gene expression displayed an upward trend once E treatment began. Most notably, this expression more than doubled after 72 hr
of E hormone therapy. Contrastingly, (b) P‐ and (c) E + P‐treated cells had IGF‐1R expression levels that were relatively the same over the
course of the experiment, suggesting that these hormone treatments had little to no effect. (d) E‐treated cells exhibited FoxO3 levels that
significantly declined. Statistical differences were observed throughout the course of HRT. (e) P, and (f) E + P displayed similar trends in
which FoxO3 expression levels dramatically decreased after 4 hr of treatment; however, gene levels began to somewhat increase, especially
by 24 hr. The statistical differences are relative to the untreated cells at 0 hr. Statistical test: 1‐way ANOVA followed by Bonferroni;
*p < 0.05, **p < 0.01, ***p < 0.001. Comparison among the hormone‐treated cell groups after 72 hr of HRT for (g) IGF‐1R and (h) FoxO3
gene expression. (g) E maintained high IGF‐1R levels over time; meanwhile, E + P cells displayed gene expression levels that continued to
decline at 72 hr, causing this cell group to have the lowest expression. A significant difference was observed for the E + P group relative to
the E group. (h) Although E had FoxO3 expression levels that were lower than both P and E + P SVK‐1 cells, no significant differences were
observed among the groups at 72 hr. Statistical test: Welch's t test followed by Bonferroni; *p < 0.033
changes were seen as early as 3 months at 32 and 64 ms (Figure 3e).

Figure 4a. P animals displayed P4 amplitude values that progres‐

The fact that the Pb and the male groups displayed similar trends in P1

sively worsened throughout the experiment. For example, baseline

amplitude values imply that ARHL‐induced auditory temporal process‐

P4 amplitude level of 0.82 mV declined by 0.26 mV at 6 months into

ing deficits are occurring in the mice at middle age—18 months. None

hormone therapy for 64‐ms gap intervals (Figure 4b). This value

of the animal hormone groups had P1 amplitude levels that reverted

dropped to 0.5 mV by the end of the recovery/washout period.

back (or close) to baseline values during the recovery period; there‐

Meaningful changes were seen at 16, 32, and 64 ms for recovery.

fore, the effects of long‐term HRT are indeed permanent.

Compared to P1 amplitude levels, P4 amplitude values continued to

P4 amplitude levels for NB2 in Figure 4 illustrate various changes

decrease during the recovery period for the P group. This indicates

among the HRT groups. E‐treated animals had relatively stable am‐

that P4 amplitudes showed preferential worsening, relative to P1,

plitude levels while undergoing HRT and during the recovery period.

after treatments were discontinued. This suggests relatively negative

Thus, no statistical differences were observed for the E group in

effects on the auditory brainstem. E + P proved to be detrimental
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to auditory function as displayed in Figure 4c. P4 amplitude levels

displayed statistical differences over the entire time course of hor‐

drastically diminished, especially at longer gap intervals. At 64 ms,

mone therapy (Figure 5d). More specifically, SVK‐1 cells undergoing

the average baseline level of 0.97 mV dropped to 0.42 mV during the

E therapy had FoxO3 levels that were reduced to a value of 0.51 at

recovery period. Similar to P animals, amplitudes declined during the

4 hr. The gene expression gradually changed to 1.64 by 24 hr, which

recovery period for all of the gap durations, suggesting that E + P

is about half of the untreated cell's FoxO3 expression value; 48 hr

worsens temporal processing abilities for P4 even after treatment

later, gene levels began to decline once again, reducing the value

has ended. Pb animals displayed the most rapid regression in ampli‐

to 0.93 by the end of the experiment. This similar pattern was ob‐

tude levels among the female groups. Notable variations were ob‐

served less dramatically in P‐ and E + P‐treated cells. As presented in

served at all of the gap intervals, particularly for gaps of 16 ms or

Figure 5e, SVK‐1 cells treated with P had FoxO3 levels that notably

longer, as seen in Figure 4d. Intriguingly, most of the recovery ampli‐

declined in a span of 12 hr. Similarly, E + P cells displayed a down‐

tude levels resembled those values seen at the 6‐month checkpoint.

trend gene expression value of 0.66 at 4 hr (Figure 5f). These re‐

Lastly, the male group displayed fewer age‐related changes than the

sults strongly suggest that E and, to a lesser extent, P modify FoxO3

Pb group for P4 amplitude levels at the shorter gap durations, but

levels in the cochlea. However, the reason for the variability in the

just as severe declines for the longer gaps. Specifically, significant

gene expression at the different time points is not fully understood.

changes occurred at 3 months for 32 and 62 ms (Figure 4e). Similar

There is a possibility that E treatment causes a downtrend in FoxO3

to Pb, these changes are strong indications of brainstem temporal

gene levels, seeing that at 72 hr of treatment this was the only group

processing deficits characteristic of ARHL. However, in this case, the

that had diminishing expression values. Interestingly, P and E + P

males show smaller declines at the shorter gap durations than the

had higher FoxO3 expression levels among the cell groups through‐

E + P and Pb females.

out the experiment, with values of 1.5 and 1.73, correspondingly
(Figure 5e,f,h). This indicates that E not only maintains lower FoxO3

2.3 | In Vitro SVK‐1 cells display increases in IGF‐1R
expression during hormone treatment

levels in the auditory system over time, but does so more effectively
than P. This reduction in FoxO3 expression may activate another
component in the PI3K/AKT pathway to assist cochlear cells with

A focal purpose of the present study was to investigate key proper‐

neuro‐protective activities. Further testing should be done to de‐

ties of the PI3k/AKT pathway and its role in cochlear cell survival as

termine whether the declines in expression seen during treatment

well as anti‐apoptotic responses, which can be regulated by IGF‐1R

improve or worsen for longer time periods.

and FoxO3 genes. In vitro studies were performed to observe the
expression of IGF‐1R and FoxO3 during the course of HRT to better
interpret the findings from electrophysiology experiments. SVK‐1
cells were treated with E, P, or E + P and were evaluated in a time‐

2.4 | In Vivo SV tissue samples exhibit lingering
effects post‐treatment

dependent manner: 4, 12, 24, 48, and 72 hr. (Untreated cells are de‐

In vivo SV tissue samples were utilized to evaluate the 1‐month

noted at 0 hr and served as the control.) E‐treated cells were the only

aftermath effects of long‐term HRT in the peripheral auditory

group to demonstrate an increasing trend with time for IGF‐1 levels,

system. These results were also used to validate the findings ob‐

as seen in Figure 5a. Fold change expressions that were initially 0.56

tained from molecular experiments using SVK‐1 cells (this section).

at 4 hr rose to 2.21 toward 72 hr of E treatment, which is more than

Figure 6 shows that SV tissue samples from E‐treated animals had

twice the starting value. It should be noted that IGF‐1 gene expres‐

significantly higher IGF‐1R levels, by approximately threefold,

sion marginally declined, relative to untreated cells (0.86), during the

compared to the rest of the groups in the study (FHRT [5,10] = 6.50,

first few hours of treatment before the positive trend was observed.

p = 0.0061). The Pb and control female (CF; age‐matched females

In contrast, SVK‐1 cells treated with P and E + P exhibited little to

with ovaries intact) groups had the most significant differences,

no changes in expression during hormone therapy in Figure 5b,c, re‐

relative to the E group, among the other subject groups. This is

spectively. For instance, at 4 hr E + P cells had gene expression levels

an interesting finding due to the fact that neither of these female

of 0.68 that elevated to 1.5 at 24 hr and then dwindled to 1.02 at

groups underwent any type of hormone treatment. Therefore, it

72 hr. These findings indicate that over a long‐term period E could

is possible that lack of HRT, during the aging process, decreases

possibly play a key role in amplifying the expression of IGF‐1 in the

IGF‐1R levels. Conversely, FoxO3 expressions were relatively simi‐

cochlea. Meanwhile, P and combination treatment (E + P) showed

lar among all of the groups, with expression levels ranging from

no effect, which may have contributed to functional declines and

0.76 (CF) to 1.26 (P) (FHRT [5,11] = 1.43, p = 0.29). It is important to

degeneration in the auditory system observed during the electro‐

note that these are the gene expression values 1 month after HRT

physiology experiments.

was discontinued.

FoxO3 gene expression was also evaluated in hormone‐treated

In Figure 5g and 6a, e‐treated cells displayed higher levels of

SVK‐1 cells, as seen in Figure 5 (d–f, h). Untreated cells had an av‐

IGF‐1R both during and after HRT. This coincides with previous re‐

erage FoxO3 expression value of 3.14. Intriguingly, all of the HRT

ports of E's long‐lasting effect on the auditory system. E + P‐treated

cell groups had FoxO3 expression levels that decreased significantly

cells had the lowest IGF‐1R expression among the hormone groups

immediately after treatment began; however, only E‐treated cells

during the treatment period. Although E‐treated cells presented
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F I G U R E 6 In vivo 1‐month post‐treatment IGF‐1R and FoxO3 expression levels. (a) E animals had the highest IGF‐1R fold expression
levels among the subject groups for SV tissue samples. Interestingly, Pb and control female (CF) animals had the most significant
differences among the groups, relative to E. This implies that lack of HRT during the aging process could possibly decrease IGF‐1R levels.
(b) FoxO3 gene expression was comparatively similar among the SV tissue sample groups. Congruous findings were observed for in vitro
FoxO3 experiments. It can be noted that overall the CF group had the lowest expression levels for both genes. (c) Post‐treatment IGF‐1
concentration levels in the serum of HRT mice showed no significant differences among the female HRT groups. Only E + P and Pb groups
displayed statistical variances in comparison to the control male animals. Statistical test: 1‐way ANOVA followed by Bonferroni; *p < 0.05,
**p < 0.01 (E n = 3; P n = 3; E + P n = 3; Pb n = 3, Males n = 3; CF n = 3). Note: The CF group consists of age‐matched females with their
ovaries intact that did not undergo any type of HRT
somewhat of a lower trend for FoxO3 levels compared to E + P

consistently had lower auditory thresholds during the recov‐

SVK‐1 cells, no significant changes were observed after 72 hr of hor‐

ery/washout period than all of the other HRT groups (Refer to

mone therapy for any of the groups (Figure 5h). Parallel results could

Figure 2f). Price et al. (2009) observed similar results with ABR

be seen among the hormone groups for in vitro and in vivo IGF‐1R

thresholds in middle‐aged female mice treated with E for 4 months

and FoxO3 gene expressions. These findings suggest the theory that

compared to age‐matched mice treated with E + P for the same

IGF‐1R and FoxO3 may have an inverse relationship with one an‐

amount of time and their male control group. It should be noted

other during sex hormone therapy.

that the ovaries for the CBA/CaJ female mice used in the Price et

Additionally, serum IGF‐1 expression levels were taken from an‐

al. (2009) study were intact throughout the course of the treat‐

imals that underwent HRT for the duration of 6 months, followed

ment. Similarly, postmenopausal women treated with E for a mean

by the 1‐month recovery period, which are shown in Figure 6c.

of 3.35 ± 2.20 years had consistently lower air conduction thresh‐

Significant differences were only seen between the E + P, Pb, and

olds than women who received no treatment and women who were

male control groups. These findings indicate that hormones have

undergoing combination hormone therapy for 4.13 ± 2.41 years

somewhat of an impact on IGF‐1 levels, albeit no significant differ‐

(Kilicdag et al., 2004). As for P1 and P4 amplitude levels for gap

ences were observed for any of the females.

coding experiments (NB2, in the present study), minimal changes
were also observed. P1 amplitude values for 3 months, 6 months,

3 | D I S CU S S I O N
3.1 | E's Neuro‐protective properties in the cochlea

and recovery were essentially the same for the E group at a major‐
ity of the gap durations (Figure 3a). Likewise, P4 amplitude levels
remained relatively stable once hormone therapy began. These
findings support Coleman and colleagues (1994) work with 3‐

Our study showed positive findings for E‐treated animals that can

month ovariectomized (OVX) rats treated with E that maintained

be used to expand on the theory that this hormone has neuro‐

high amplitude levels compared to OVX rats that did not receive

protective properties in the auditory system that could possibly

any treatment. Analogously, Wharton and Church (1990) observed

prevent or delay key aspects of presbycusis. As presented above,

declining ABR amplitude values in young women (19–25 years of

the E group displayed minimal changes in ABR thresholds while

age) relative to old females (50–75 years of age). Young women had

undergoing HRT (Figure 2a). Additionally, this group of animals

amplitude values of 0.41 mV that drastically declined to 0.3 mV in
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older women for ABR Wave V (P4 mouse equivalent) at 80 dB.

to the rest of the subject groups (Figure 6a). These results support

Contrarily, their young and old male counterparts had amplitudes

the growing evidence that E and IGF‐1R may have a co‐dependent

with a difference of only 0.01 mV for Wave V at 80 dB. This steep

relationship with one another in the aging cochlea.

age‐related decline in female amplitude levels in the Wharton and

Recent findings from other physiological systems support

Church (1990) study was more than likely due to the decrease of E

the growing evidence that E has a positive relationship with

in postmenopausal women aged 50+.

IGF‐1R, in order to manage oxidative stress and promote cell sur‐

These lines of research have come a long way in explaining E's

vival (Rodriguez‐de la Rosa, Lassaletta, Calvino, Murillo‐Cuesta,

protective benefits for the peripheral and central auditory sys‐

& Varela‐Nieto, 2017; Sohrabji, 2015). Olivieri et al. (2014) found

tems (Frisina & Frisina, 2013; Jerger & Hall, 1980). To date, there

that IGF‐1R expression levels doubled in MCF‐7 cells when E dos‐

are several theories as to how E preserves auditory function both

ages were raised from 10 to 100 nM. This increased expression of

directly and indirectly. The leading theory is that E assists in the

IGF‐1R proved to have beneficial value on cell signaling, mobility, and

regulation of neuron survival, which is an important neurotrophic

muscle power in the skeletal muscle of postmenopausal women un‐

component that is lost during the aging process. Estrogen re‐

dergoing HRT. This study concluded that E increases activity in the

ceptor (ER) subtypes, ERα and ERβ, have been identified in the

IGF‐1 pathway, significantly delaying the atrophy of skeletal muscle

inner ear, in areas such as the stria vascularis (SV), cochlear blood

in HRT users. Therefore, the results of the present study can be in‐

vessels, and spiral ganglion (SG) type I cells. ERα has been linked

terpreted commensurately: High IGF‐1R expression levels that were

to alterations of cochlear and vestibular sensory transduction;

observed in E‐treated SVK‐1 cells were protecting cochlear sensory

meanwhile, ERβ is associated with the survival of neurons in the

cells from degeneration. This is further supported by the fact that

auditory system (Garcia‐Segura, Azcoitia, & DonCarlos, 2001; He

various studies have found that E improves and maintains auditory

& Ren, 2018; Meltser et al., 2008; Motohashi et al., 2010). From

function via its neuro‐protective properties. As mentioned above,

this knowledge base, it has been proposed that ERβ could pos‐

one of the main theories for how this occurs is ERβ association with

sibly play a significant role in the ascending auditory pathway in

the survival of cochlear cells (Hultcrantz et al., 2006; Motohashi et

transmitting information from the cochlea to the brain more ef‐

al., 2010; Stenberg et al., 2003). Perhaps there is cross talk specif‐

fectively. It is well known that for hearing transduction, sound

ically between ERβ and IGF‐1R pathways in the auditory system. A

waves are converted into electrochemical signals via the inner hair

pioneering study carried out by Toran‐Allerand et al. (1988) showed

cells (IHCs). IHCs synapse primarily with type I SG cells, exciting

that cultures of the olfactory bulb, hypothalamus, preoptic area, and

the auditory nerve, which in return relays sound information to

cerebral cortex treated with E and high levels of insulin exhibited

the central auditory regions of the brain. The synchronization and

significant increases in neurite outgrowth. This increase in neuronal

number of SG cells that respond to a sound stimulus determine

growth was limited to areas that only had ERs. Quesada et al. (2007)

the amplitude and latency of ABR waves (Williamson et al., 2015).

found that SNpc DA neurons found in the brain were immunoreac‐

Therefore, attenuating amplitude levels and increasing latency val‐

tive for ERβ and IGF‐1R, which helps to explain why E's neuro‐pro‐

ues are correlated with ERβ degeneration in the auditory system

tective effects are related to IGF‐1. It should be noted that ERα was

(Charitidi & Canlon, 2010; Charitidi, Meltser, Tahera, & Canlon,

not identified in this particular neuron. Furthermore, primary corti‐

2009; Stenberg, Simonoska, Stygar, Sahlin, & Hultcrantz, 2003;

cal neurons treated with the excitatory neurotransmitter glutamate

Stenberg et al., 2001). Previous studies that support this theory in‐

to induce neuronal death, exhibited signs of neuro‐protection with

clude Hultcrantz, Simonoska, and Stenberg (2006) who found that

decreased cellular lactate dehydrogenase (LDH) levels after being

ERβ knockout mice displayed rapid declines in auditory function as

administered E. (Singer, Rogers, Strickland, & Dorsa, 1996). LDH lev‐

early as 12 months, which eventually led to severe degeneration

els increased in pretreated E cells given Tamoxifen (the major blocker

throughout the parts of the brain used for hearing after 1 year.

of ERs used clinically) over a 24‐hr period, reversing any signs of

Furthermore, Rudzinski and Krejza (2002) observed that E ligand

neuro‐protection.

interactions with ERs increase with the up‐regulation of growth

The fact that E activates many biological events leads to a num‐

factors and specific genes (IGF‐1 and FoxO3) responsible for cell

ber of possibilities of which downstream pathways are involved in

proliferation, metabolism, and anti‐apoptotic cellular responses.

this neuro‐protection in the auditory system. In the present study,

Therefore, it is possible that steady levels of E help to keep ER's

we hypothesized that AKT phosphorylated by IGF‐1 would activate

intact, which could delay the degeneration of cochlear cells and

FoxO3 gene expression, which would inhibit the DNA transcription

auditory neurons. The molecular pathway findings for E therapy of

of pro‐apoptotic genes (i.e., BIM, Fas ligand) via the PI3K/AKT path‐

the present report also strongly support these conclusions.

way (Kops et al., 2002). In response, cochlear cells would be safe‐

The findings from this study imply that E may have a beneficial

guarded from apoptosis and the signs of ARHL would be delayed.

effect on IGF‐1R expression in the cochlea since E‐treated SVK‐1

Previous studies have found that forkhead transcription factor,

cells displayed an upward trend for IGF‐1R levels during a 72‐hr time

FoxO3, plays a role in preserving auditory function (Gilels, Paquette,

span (Figure 5a). Even more interesting was the in vivo finding that

Beaulac, Bullen, & White, 2017; Gilels, Paquette, Zhang, Rahman, &

IGF‐1R expression levels were significantly high 1‐month post‐treat‐

White, 2013). Nonetheless, FoxO3 gene expressions statistically fell

ment in SV samples extracted from the cochlea of E mice compared

from 3.14 to 0.51 after only 4 hr of E treatment (Refer to Figure 5d).
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These levels suddenly increased after 12 and 24 hr; however, FoxO3

system still remain unclear. Very few hormone‐based studies have

gene expression values began to dwindle at 48 hr. Similar trends

evaluated auditory function for subject groups treated with only P.

could be seen among all of the hormone groups in Figure 5 d‐f.

Possibly because researchers surmise that P's effects on the audi‐

By 72 hr, the E group had a downtrend of FoxO3 levels, especially

tory system are indirect (Bonnard, Sahlin, Hultcrantz, & Simonoska,

compared to E + P cells. Parallel results could be seen with in vivo

2013). It has been speculated that since E has such a positive impact

post‐treatment experiments (Figure 6b). Surprisingly, the up/down

on the auditory system, P must be the negative component of the

inclination of FoxO3 levels observed in SVK‐1 cells did not mirror the

hormone duo, E + P. For instance, E + P has been shown to be det‐

results of the serum levels obtained during HRT in vivo experiments.

rimental to hearing thresholds in various human and animal stud‐

That does not mean, however, that changes did not take place in

ies (Guimaraes et al., 2006; Kilicdag et al., 2004; Price et al., 2009).

cochlear cells during treatment. FoxO3 is heavily regulated by the

This theory includes the notion that P acts as an inhibitor to balance

phosphorylation of AKT based upon environmental conditions.

out the excitatory, neurotrophic effects of E. For instance, high lev‐

Untreated SVK‐1 cells had qPCR values of 0.86 and 3.14 for IGF‐1R

els of P and its metabolites can potentially activate the synthesis

and FoxO3 expression levels, respectively. All of the cells that were

of an inhibitory neurotransmitter known as GABA, which leads to

administered E had FoxO3 levels that displayed lower expression

an increase in inhibitory synaptic transmission in the brain and the

values than control cells, most significantly at 72 hr. IGF‐1R levels, on

cochlea, disrupting the normal balance of excitatory and inhibitory

the other hand, displayed a continually upward trend for E‐treated

drives (Guimaraes et al., 2006; Rogawski, 2003). This rise in inhibi‐

cells over the course of the experiment. It is possible that the upward

tion may degrade auditory threshold sensitivity and supra‐threshold

proclivity of IGF‐1R led to the downtrend of FoxO3 in the cochlea,

responses. Contrarily, E is believed to have the opposite effect, by

as a concurrent response. For instance, a study that was performed

decreasing GABA levels in the brain and cochlea to more favora‐

using MCF‐7 cells discovered that IGF‐1R expression increased with

ble amounts (Ledoux & Woolley, 2005). This logic can explain the

incremental dosages of E; however, FoxO3 levels remained the

negative impact that P had on ABR thresholds for the present study

same after 10 and 100 nM of E treatment (Olivieri et al., 2014). It is

(Figure 1b). However, favorable auditory responses were observed

possible that the vast increase of IGF‐1R in SVK‐1 cells could have

for the ABR GIN amplitude levels for P‐treated animals. Therefore,

activated another signaling pathway to prevent apoptosis from oc‐

although P is not as consistently beneficial as E, under certain cir‐

curring without the need to accumulate FoxO3. This suggests that

cumstances P alone may possibly possess some neuro‐protection

FoxO3 is not a primary gene that induces survival in cochlear cells

properties in the auditory system. This theory is somewhat congru‐

in the IGF‐1 pathway during HRT (Zekas & Prossnitz, 2015). More

ous with the findings from the in vitro (during treatment) and in vivo

research is needed to confirm which related cell signaling genes are

(post‐treatment) molecular experiments in the present study. Little

activated by IGF‐1R to stimulate the PI3K/AKT pathway to prevent

to no changes were observed for the IGF‐1R gene expression values

apoptosis.

for P‐treated SVK‐1 cells (Figure 5b). However, there were no sta‐
tistical differences between IGF‐1R levels for E‐ and P‐treated cells

3.2 | P's controversial impact on auditory
functionality

at 72 hr, unlike the E + P group. FoxO3 levels were notably reduced
compared to untreated cells, particularly at 4 and 12 hr of treatment
as seen in Figure 5e. Post‐treatment results show that P‐treated ani‐

Initially, P seemed to have a negative impact on OVX mice as seen

mals had relatively similar IGF‐1R and FoxO3 gene expression values

in Figure 2b. As soon as treatment began, ABR thresholds increased

(Refer to Figure 6). These data suggest that P may have displayed

drastically by 10 dB for high frequencies at 3 months. This escala‐

protective properties for cochlear cells during treatment, similar to

tion continued throughout the course of hormone therapy. By re‐

the P4 amplitude level results previously mentioned. Consistent with

covery time, thresholds shifts were approximately 20 dB for higher

this, several studies have found that P increases neurogenesis and

frequencies, relative to the baseline. No recovery was observed.

neuron survival in the brain (Chan, Chow, Hamson, Lieblich, & Galea,

Interestingly, ABR GIN amplitude values for P1 and P4 for NB2

2014; He, Yang, Zhai, Shao, & Li, 2011; Si et al., 2013). For instance,

gradually declined for P‐treated animals. For smaller gap durations,

male rats with traumatic brain injury (TBI) exhibited significantly

baseline values and 3‐month values were comparatively the same

lower levels of cyclooxygenase‐2 (inflammation) and caspase‐3

for P1. Signs of auditory deterioration were present after 6 months

(apoptosis) after being treated with P (Si et al., 2013). Additionally,

of treatment. Significant differences can be seen for 6 months and

Berent‐Spillson et al. (2015) reported that postmenopausal women

recovery for wider gap intervals, such as 32 and 64 ms. A similar

treated with P had the same improvements in verbal processing and

trend could be seen with P4 amplitude values, but significant differ‐

verbal working memory as women treated with E, for postmenopau‐

ences were seen only at recovery. Once treatment ended, P4 ampli‐

sal women treated with HRT for a 90‐day period. It should be noted

tudes dropped to nearly 50% compared to baseline values. This is an

that verbal processing is related to auditory temporal processing. In

indication that P exhibits some type of protection for temporal pro‐

another neuroscience report, mice treated with 20 mg of P displayed

cessing in the brainstem (lateral lemniscus/IC), since P4 waves are

a 6‐fold reduction in vacuolated motoneurons and a reduction in

believed to be generated from that region of the brain (Williamson et

nitric oxide synthase (NOS) active neurons, both of which are as‐

al., 2015). It should be noted that P's overall effects on the auditory

sociated with neurodegenerative conditions, including amyotrophic
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proved certain symptoms of this disease in the mice over time.
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types of findings by reporting histological changes of inflammation
infiltrate and vacuolization of the SV in guinea pigs treated with E + P.

Although quite a few studies have shown the positive influence

The molecular findings from the present study also suggest that in‐

of P in the brain after traumatic injuries or neurological diseases, P's

flammation could be occurring linked to increases in apoptosis. For

impact on the auditory system is still debatable. Our overall find‐

example, in vitro IGF‐1R gene expression was significantly lower for

ings show that P can have negative impacts on ABRs; however, ABR

E + P‐treated cells, especially compared to the E group. Meanwhile,

GIN amplitude levels seem to show P's abilities to possibly preserve

FoxO3 gene expression demonstrated an upward trend for E + P

certain aspects of auditory system functionality for temporal pro‐

cells among the hormone groups, notably at 72 hr (Figure 5h). Even

cessing mechanisms. Further investigation needs to be done to gain

though FoxO3 levels were high for E + P cells, this value was low

better insights into P's general role in hearing and aging.

compared to untreated control cells (Figure 5f). Therefore, FoxO3’s
ability to inhibit pro‐apoptotic genes and/or remove toxins from

3.3 | Combination therapy's detrimental influence
on hearing

the cell via the activation of autophagy‐related genes may have
been jeopardized (Vasudevan & Garraway, 2010). This could have
prevented the cell from creating a healthy environment to main‐

Prior work has shown that combination treatment has a negative

tain homeostasis and overall integrity; thus, catalyzing the signs of

impact on the auditory system. In the present study, E + P had a

aging within the auditory system. Notably, low IGF‐1R levels could

detrimental effect on ABR thresholds compared to E and Pb ani‐

not compensate the protection initially provided by FoxO3, unlike

mals. Threshold values increased by about 10 dB immediately after

what was observed for E cell group. There are still very few studies

treatment began, and leveled off during the 6‐month period. ABR

that have looked into the negative impact of combination treatment

Recovery/washout thresholds in Figure 2f show that the E + P group

on the auditory system from cellular and biomarker perspectives.

has the second lowest thresholds indicating that this group per‐

Optimistically, these findings will contribute to better understanding

formed slightly better in ABR's than all of the female hormone groups

how E + P exacerbates ARHL as well as lead to more hormone‐based

except for E. P1 ABR GIN amplitude values for E + P animals present

molecular mechanism investigations in the future.

a sharp reduction immediately after undergoing HRT. Amplitude

In conclusion, female sex hormones, E in particular, modified

levels were cut roughly in half by the 3‐month checkpoint for all of

IGF‐1R and, to a lesser extent, FoxO3 expression via the PI3K/AKT

the gap durations, relative to the baseline. For instance, baseline

pathway in the mammalian cochlea to promote sensory cell health,

values that started at 1.5 μV were drastically reduced to ~0.8 μV

and delay certain key aspects of ARHL. These effects appear to be

after 3 months at 32 ms. Similar to the ABR thresholds, this decline

long lasting in females undergoing hormone treatment. Additionally, P

subsided during the 6‐month and recovery period. These findings

therapy generated conflicting results by both increasing ABR thresh‐

suggest that the negative effects of combination treatment occur at

olds but slowing temporal processing deficiencies in ABR GIN ampli‐

a faster pace than compared to P, whose group's amplitude values

tude levels associated with aging during the course of HRT treatment.

gradually decreased over the course of the experiment (Figure 3).

This strongly suggests that P may not be as detrimental to the au‐

On the contrary, P4 amplitudes exhibited signs of auditory decline

ditory system as initially thought. Overall, understanding how sex

at a steadier rate compared to P1. Significant differences were high‐

hormones influence auditory function will help menopausal women,

lighted between baseline and recovery values. Interestingly, ampli‐

who are considering HRT, make more informed decisions that best

tude levels decreased for most of the gap intervals after treatment

suits their needs, enhance therapeutic options for ARHL, and possibly

was discontinued. Similar to the results found with the P group, com‐

lead to more successful research about the relations between hor‐

bination treatment may have had some marginal auditory benefits

mone levels and other neurodegenerative diseases or dementias, such

while being administered for P4 but not P1. These findings suggest

as Alzheimer's disease, which have been associated with presbycusis.

that E + P may have more of a long‐lasting negative impact on the
auditory nerve (P1) as opposed to the IC (P4). Perhaps E + P directly
or indirectly affects the auditory nerve fibers. Studies have found
that declines in cochlear neurons, seen with aging, can limit the ex‐
citatory effects of the auditory nerve during a noise stimulus. Hence,
a less than robust P1 will be generated.

4 | M E TH O D S — E X PE R I M E NTA L
PRO C E D U R E S
4.1 | Animals

Several reports have shown that E + P raises ABR thresholds as

For the present study, 70 CBA/CaJ middle‐aged mice were used; 53 fe‐

well as reduces ABR amplitude level values. Price et al. (2009) pre‐

males and 17 males. Baseline testing was performed at 15 months on all

sented statistical differences in ABR thresholds and DPOAE ampli‐

of the animals. All of the female mice underwent an ovariectomy proce‐

tudes in E + P postmenopausal mice after 4 months of treatment.

dure, where both sets of ovaries were removed, once baseline testing

This particular subject group was the only group of animals to display

was complete. This was done to ensure that no naturally occurring sex

notable deficits in DPOAE amplitudes for all frequencies. Similar re‐

hormones would have any effects. The females were then randomly

sults were presented by Guimaraes et al. (2006) in post‐menopausal

placed in hormone treatment groups that consisted of E‐estradiol 17β

women. In 2001, Bittar and colleagues attempted to explain these

(n = 16, 0.006 mg/day), P (n = 12, 0.40 mg/day), E + P (n = 12, 0.40 mg/
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day +0.006 mg/day), and placebo (Pb, n = 13). It should be noted that

were placed in RLT Buffer and then extracted using the same pro‐

a group of males served as a comparison control group. Hormone

tocol as the SVK‐1 cells, previously mentioned. The samples were

therapy was administered in the form of a subcutaneous slow‐release

categorized according to the treatment each animal received: E

pellet. The pellets were designed to release hormones for a duration

(n = 4, 0.006 mg/day), P (n = 4, 0.40 mg/day), E + P (n = 4, 0.40 mg/

of 3 months and were inserted between the neck and the shoulder of

day +0.006 mg/day), and placebo (Pb, n = 3). 50 ng for each of the

the animals immediately after the ovariectomy surgery. A second pel‐

following RNA samples was then used to synthesize 20 µl of cDNA

let was inserted in the animals after 3 months, ensuring that the fe‐

using an iScript cDNA kit (Bio‐Rad Laboratories; Hercules, CA). Once

males underwent continuous hormone therapy for a total of 6 months.

the sample mixtures were made, they were incubated for 5 min at

A 1‐month recovery/washout period took place to see whether there

25°C (priming), 20 min at 46°C (reverse transcription), and 1 min at

were any lingering side effects after HRT was discontinued. CBA/CaJ

95°C (RT inactivation). Primer sequences used to detect the genes

breeders were obtained from the Jackson Labs (Bar Harbor, ME) and

were as follows: IGF‐1R, sense 5′‐TTGCCCTAAAACTGAAGCTGA‐3′;

were bred at the University of South Florida (USF) Vivarium. All of the

anti‐sense

animal protocols used for the following study were approved by the

sense

USF Institutional Animal Care and Use Committee (IACUC).

5′‐GTTCTCGCAAAGACGAAGTTG‐3′

5′‐GTTCAATGGGAGCTTGGAAT‐3′;

and

Foxo3,

anti‐sense

5′‐

CAACCCGTCAGCATCCATGA‐3′. Primer specificity was performed
as previously described in Ding, Walton, Zhu, and Frisina (2018).

4.2 | Electrophysiology experiments

Triplet repeated quantitative PCR (qPCR) experiments were exe‐
cuted by creating a master mix using the following primers, SSoFast

Throughout the course of the experiment, the animals hearing was

EvaGreen (Bio‐Rad, Hercules, CA), and the cDNA samples. The sam‐

thoroughly tested at different checkpoints: baseline (before surgery

ples were then placed in a CFX™ Real Time PCR system to generate

and prior to HRT), 3, 6 and 1 month (post‐HRT). Auditory testing

a quantitative analysis of the gene expressed in both SVK‐1 cells and

consisted of auditory brainstem responses (ABRs) and ABR gap‐in‐

SV tissue samples. It should be noted that the relative standard curve

noise (GIN). Further details about ABR and ABR GIN testing tech‐

method was used when analyzing the data for the following samples.

niques can be found in our previous, detailed report Williamson et
al. (2015). For the animals that completed the study, tissue and blood
samples were collected and stored for anatomical and molecular ex‐
periments described below.

4.5 | ELISA assay
Blood samples were extracted from animals after undergoing HRT
treatment for 6 months and a recovery/washout period that lasted

4.3 | Cell culture and hormonal treatments

1 month. The blood was set to clot in lukewarm water for ~15 min
and then centrifuged for 20 min to allow separation. The serum was

SVK‐1 epithelial cells derived from the SV of the P14 Immortomouse

then collected and stored at −80°C for future use. Serum IGF‐1 con‐

(obtained from Dr. Federico Kalinec, Univ. South. Cal.) were utilized.

centrations were quantitatively assessed for all of the following sam‐

DMEM medium (Corning, Manassas, VA) with 10% FBS was used to

ples utilizing manufacture's protocol for an IGF‐1 Quantikine ELISA

proliferate the cells. Initially, the SVK‐1 cells were incubated at 33°C

Kit (R&D Systems, Minneapolis, MD, USA). It should be noted that an

in a humidified 10% CO2 atmosphere in a proliferation stage. At least

intra‐assay precision technique was implemented when the follow‐

24 hr before treatment, the cells were then placed in a differentiation

ing experiment was performed.

setting of 39°C and 5% CO2 to ensure that the cells successfully ma‐
tured to SVK‐1 epithelial cells in serum‐free DMEM. Once the optimal
dosage was determined, the cells received 10 nM of hormone treat‐

4.6 | Data statistical analysis

ment (E, P, or E + P) for various time durations, which included 4, 12, 24,

GraphPad Prism7 was used to perform the statistically analysis for

48, and 72 hr. 10 nM was the optimum dosage for HRT treatment for

the following experiments. Statistical tests, such as 1‐way ANOVA,

cells according to previous studies (Duenas, Torres‐Aleman, Naftolin, &

2‐way ANOVA, and Welch's t test, were used, depending on the

Garcia‐Segura, 1996; Olivieri et al., 2014). It should be noted that cells

design of the experiment. Bonferroni pairwise comparisons are re‐

were administered HRT at a confluence of ~80% for treatment dura‐

ported when the main effects of the ANOVA F statistics are statisti‐

tions of 24 hr or less. Hormone therapy lasting more than 24 hr began

cally significant. Results were identified as statistically significant if

when a confluence of ~30% was obtained to increase the number of

p < 0.05. A more detailed description about the statistical analysis

healthy cells that would be collected once treatment ended.

can be found in the previous publication Williamson et al. (2015).

4.4 | PCR experiments
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